Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lupin's partnership program is designed to foster collaborations with companies looking to extend their product lifecycles
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population
These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~
Investment to expand manufacturing and global medicine supply capacity
Subscribe To Our Newsletter & Stay Updated
